There are more than 10,000 articles in the literature published since 1999 that appear in a search of hyperuricemia and hypouricemia for vascular events. Systematic reviews were reviewed for this time frame, numbering approximately 300 articles in addition to more than 400 reports of randomized clinical trials published since 2017. In summary, the epidemiologic associations of hyperuricemia and hypouricemia with vascular disease are confounded by comorbid conditions. The interventional data are suggestive of a relationship of gout and vascular disease and to a lesser extent hyperuricemia and hypertension; however, more interventional studies are necessary to confirm these relationships.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rdc.2019.04.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of N-phenyl-N-(quinolin-4-yl) amino carboxylic acids as URAT1 inhibitors with hypouricemic effects.
Bioorg Med Chem Lett
March 2025
Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; State Key Laboratory of Digestive Health, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Electronic address:
Urate transporter 1 (URAT1) is a therapeutic target for the treatment of hyperuricemia and gout. However, the application of currently marketed URAT1 inhibitors is hampered by insufficient efficacy and poor safety profiles. A series of N-phenyl-N-(quinolin-4-yl) amino carboxylic acids were designed by adopting strategies of molecular hybridization, scaffold hopping, and functional variation.
View Article and Find Full Text PDFFunctional identification of soluble uric acid as an endogenous inhibitor of CD38.
Elife
November 2024
Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Article Synopsis
- - Excessive or insufficient levels of soluble uric acid (sUA) are linked to various health issues, while sUA at normal levels appears to be important for overall health, though its specific functions are not well understood.
- - This study shows that sUA can inhibit the enzyme CD38, which is involved in the breakdown of NAD, through a reversible non-competitive mechanism, particularly affecting purine metabolism.
- - At physiological levels, sUA may help to reduce systemic inflammation and peritonitis in mice, suggesting a significant role in regulating NAD availability and supporting the immune system by interacting with CD38.
A Closed-Loop Cascade Strategy for On-Demand Regulation of Uric Acid.
Adv Healthc Mater
January 2025
School of Pharmaceutical Sciences, Cixi Biomedical Research Institute, Wenzhou Medical University, Zhejiang, 325035, P. R. China.
Article Synopsis
- * A new system called NW-FPNP/uricase (UOX) is proposed for precise UA regulation, using a biocompatible network that responds to UA levels and dynamically balances UA production and breakdown.
- * This innovative approach aims to improve treatment safety by preventing drug overdoses and avoiding low uric acid levels, representing a significant advancement in managing UA levels effectively.
Fluorescent Determination of Uric Acid Based on Porphyrin and ZnCoO Nanocomposite.
J Fluoresc
October 2024
Department of Applied Chemistry, Cochin University of Science and Technology, Kochi, 682022, Kerala, India.
Article Synopsis
- Advances in porphyrin chemistry led to the creation of a TCPP-ZnCoO composite for use in a novel optical sensor targeting uric acid detection.
- The synthesis involved a simple one-pot hydrothermal method, and the composite's characteristics were analyzed using various spectroscopic techniques.
- The developed sensor demonstrated high sensitivity, with a detection limit of 0.015 nM, effectively quantifying uric acid in human urine samples.
Drug-Induced Hypouricemia.
Drug Saf
September 2024
Intensive Care, Department of Intensive Care, Sahloul Hospital, University of Sousse, Sousse, Tunisia.
Hypouricemia is defined as a serum uric acid concentration of ≤ 2.0 mg/dL or 119 μmol/L. Hypouricemia may occur secondarily to a number of underlying conditions, including severe hepatocellular disease, neoplasia, defective renal tubular reabsorption of uric acid, inherited metabolic defect in purine metabolism, and drugs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!